The invention belongs to the field of medical detection, and particularly relates to an SARS-CoV-2 susceptible gene combination and application in preparation of a COVID-19 susceptible population screening kit. The human gene combination disclosed by the invention is KIR2DL2 and HLA-C, and specifically is HLA-C*01, HLA-C*02, HLA-C*03, HLA-C*04, HLA-C*05, HLA-C*06, HLA-C*07, HLA-C*08, HLA-C*09, HLA-C*10, HLA-C*12, HLA-C*14, HLA-C*15, HLA-C*16 and HLA-C*17. At present, early-stage prediction related researches on the occurrence of SARS-CoV-2 virus infection and susceptible populations do not exist in the world. The kit provided by the invention has great application value in disease susceptible population.